Trial Profile
A phase I study of rintatolimod as a potential adjuvant enhancement of Bioclones' therapeutic cancer vaccine
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Dendritic cell vaccine-Bioclones (Primary) ; Rintatolimod (Primary)
- Indications Cancer
- Focus Adverse reactions
- 22 Aug 2014 New trial record